摘要
目的:比较头孢哌酮与莫西沙星治疗肺部感染的疗效及其安全性。方法:共选入肺部感染住院患者120例,随机分为两组,其中应用头孢哌酮治疗60例、莫西沙星治疗60例。结果:头孢哌酮组有效率86.7%,莫西沙星组有效率93.3%;对致病菌株的清除率分别为83%和90.8%;不良反应发生率分别为5%与3.3%,两者临床疗效无明显差异(P>0.05)。结论:头孢哌酮与莫西沙星都是安全有效治疗肺部感染的药物。
OBJECTIVE:To evaluate the therapeutic efficacy and adverse reactions of cefoperazone vs.moxifloxacin for pulmonary infection.METHODS:120 inpatients with pulmonary infection were randomly assigned to receive cefoperazone(n=60) or moxifloxacin(n=60).RESULTS:There were no significant differences between the cefoperazone group and the moxifloxacin group in clinical efficacy(P〉0.05)(effective rate:86.7% vs.93.3%;bacterial clearance rate:83% vs.90.8%;incidence of adverse reactions:5% vs.3.3%) CONCLUSION:Both cefoperazone and moxifloxacin are safe and effective for patients with pulmonary infection.
出处
《中国医院用药评价与分析》
2009年第7期540-541,共2页
Evaluation and Analysis of Drug-use in Hospitals of China
关键词
头孢哌酮
莫西沙星
肺部感染
临床疗效
安全性
Cefoperazone
Moxifloxacin
Pulmonary infection
Clinical efficacy
Safety